NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Chembio Diagnostics, Inc. ("Chembio" or "the Company") (NASDAQ:CEMI). Investors who purchased Chembio securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cemi.

The investigation concerns whether Chembio and certain of its officers and/or directors have violated federal securities laws.

In April 2020, Chembio's Dual Path Platform ("DPP") COVID-19 antibody test was among the first such tests to be granted Emergency Use Authorization ("EUA") by the U.S. Food and Drug Administration ("FDA"). Then, on June 17, 2020, pre-market, news outlets reported that the FDA had revoked the EUA for Chembio's DPP antibody test, reportedly citing performance concerns with the test's accuracy, a determination that its "benefits no longer outweigh its risks", and "a higher than expected rate of false results." On this news, Chembio's stock price fell $6.04 per share, or 60.83%, to close at $3.89 per share June 17, 2020.

If you are aware of any facts relating to this investigation, or purchased Chembio shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/cemi. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 594317

HALIFAX, NS / ACCESSWIRE / June 18, 2020 / Namibia Critical Metals Inc. ("Namibia Critical Metals" or the "Company" or "NMI") (TSXV:NMI) today provided an update on progress on the Lofdal Heavy Rare Earths Project ("Lofdal") in northern Namibia, which is a joint venture between the Company and Japan Oil, Gas and Metals National Corporation ("JOGMEC"). As previously announced (Company press release March 11, 2020) the Lofdal Joint Venture is operating under a Term 1 budget of CD$3,000,000 with the objectives of doubling the current resource size at Area 4 with a 7,700 m drill program, testing two high priority exploration targets with 1,500 m of drilling and carrying out further metallurgical test work to optimize the processing flow sheet. Progress since stating the drill program in early March is summarized as follows:

Drilling ahead of schedule with over 50% completed at Area 4 with results from first nine holes now reported
Drill results consistent with expected grades and thickness as predicted from the resource model, targeting to double current resource size in this first drilling phase
Drill rig will now move to exploration targets at Northern Splay and Dolomite Hill
Metallurgical bulk test runs (2.7 tonnes) completed on XRF sorter with analytical results pending. XRT sorter tests underway expecting to complete bulk test runs (4.4 tonnes) by mid-July

Drill highlights of heavy rare earth enriched zones include:

22 m @ 0.29% TREO with 67.7% heavy rare earth enrichment
(including 3 meters @ 0.87% TREO with 89.0% heavy rare earth enrichment)
15 m @ 0.32% TREO with 62.5% heavy rare earth enrichment
(including 3 meters @ 0.51% TREO with 79.3% heavy rare earth enrichment)
6 m @ 0.33% TREO with 89.0% heavy rare earth enrichment
(including 2 meters @ 0.52% TREO with 93.1% heavy rare earth enrichment)

Don Burton, President of Namibia Critical Metals stated "All holes drilled to date have intersected the Main Zone as expected. As we await lab results from the remaining thirteen holes from this phase of the Area 4 drilling, it is an opportune time to move the drill to our exploration targets where we believe the potential exists to develop satellite deposits. The drill will then return to Area 4 to complete the resource drilling program. The metallurgical program is advancing well with both XRF and XRT sorting tests providing very encouraging results. The objective with sorting is to achieve a 2-3X upgrade to the deposit grade and we look forward to a comprehensive evaluation of both technologies upon completion of the bulk test runs which will use about 7 tonnes of representative sample collected from trenches at Area 4.

These are challenging times for field operations and we are extremely fortunate to have a dedicated team in Namibia that has actually exceeded the planned monthly production since start up in March. Field operations continue with strict Covid-19 protocols in place."

The Lofdal Heavy Rare Earths Project is located 450 kilometers northwest of the capital city of Windhoek in the Kunene Region of north-western Namibia. The project area covers 314 square kilometers centered on the Lofdal carbonatite complex which hosts a number of rare earth occurrences, including the Area 4 deposit (Figure 1). Mineralization at Area 4 is dominated by xenotime, which is highly enriched in heavy rare earths. Value drivers at Lofdal are dysprosium and terbium.

The current mineral resource at Area 4 has been drilled to depths of between 125 – 225 vertical meters and is estimated to be 2.88 Mt of indicated mineral resources at a grade of 0.32% TREO1 yielding 9,230 t of REO, of which 7,050 t are estimated to be heavy rare earth oxides ("HREO") and 3.28 Mt of inferred mineral resources at a grade of 0.27% TREO yielding 8,970 t of REO, of which 6,700 t are estimated to be HREO. Full disclosure is filed on SEDAR and provided in Preliminary Economic Assessment on the Lofdal Rare Earths Project, Namibia October 1, 2014 authored by David S. Dodd, The MDM Group, South Africa; Patrick J.F. Hannon, and William Douglas Roy, MineTech International Limited, Canada; Peter Roy Siegfried and Michael R. Hall, The MSA Group, South Africa.

Drilling will now move from Area 4 to test exploration targets at the Northern Splay and Dolomite Hill targets. The Northern Splay is located 10 kilometers northeast of Area 4 on an extension of the Area 4 structure, and Dolomite Hill is situated 2.5 km north of Area 4 in a separate mineralized structure (Figure 1).

Current Drilling Operations

The primary objective of the Lofdal Joint Venture is to double the current resource size with an additional 7,700 m of drilling. The Company has completed 4,447 m of drilling to date in twenty-one holes at Area 4 (Figure 2). Drilling operations have continued un-interrupted since beginning in early March and remain on schedule, however slight delays in receiving laboratory results have been realized due to Covid-19 restrictions in Namibia and Canada. These restrictions have since eased and a steady flow of analytical results is now expected to resume.

Results from the first nine holes have been received and all holes have intersected mineralization in the Main Zone (highlighted in grey) consistent with expected grades and thickness as predicted from the resource model. Drill results are reported in summary form in Table 1 and full disclosure of all individual elements is provided in Table 2.

1"TREO" refers to total rare earth oxides; "HREO" refers to heavy rare earth oxides; "heavy rare earths" as used in all Company presentations comprise europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutetium (Lu) and yttrium (Y). Light rare earths comprise lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd) and samarium (Sm). "Heavy rare earth enrichment" is the ratio of HREO:TREO, expressed as a percentage

Table 1 – Summary of Significant Drill Intercepts from Area 4 Resource Extension Program

Intercept widths are reported as down the hole widths and are not necessarily true widths. Field operations follow strict company Standard Operating Procedures with regards to drilling practices, sampling procedures, security of transport and analytical procedures as per recommendations in the Canadian Institute of Mining, Metallurgy and Petroleum CIM's Best Practices Guidelines (2018), which includes strict internal QAQC procedures for the insertion of blanks, standards and duplicates. QAQC samples account for 10% of samples submitted in each batch. Sample preparation and analytical work for the drilling program is being provided by Activation Laboratories Ltd. ("Actlabs" Windhoek, Namibia and Ancaster, Ontario) employing appropriate crushing and pulverization procedures (Actlabs Code RX-1) on half sawn core samples provided from the selected intervals, and utilizing lithium metaborate/tetraborate fusion and ICP-MS techniques suitable for rare earth element analyses (Actlabs Code 8). Activation Laboratories is an ISO/IEC 17025 accredited laboratory.

Drill intercepts confirm the highest levels of heavy rare earth enrichment ("HREE") in the central portion of the deposit together with the highest concentrations of dysprosium. A number of significant intercepts have been noted in both the hanging wall ("HW") and foot wall ("FW") to the Main Zone which are expected to contribute to the updated resource estimate that will be undertaken upon completion of the current drill program end of 2020. Representative drill sections are shown in Figure 3 and Figure 4 with Main Zone intercepts highlighted in red boxes.

Figure 1 – Geology of the project area showing the location of the Area 4 deposit and the two exploration drill targets at the Northern Splay and Dolomite Hill

Figure 2. Drill plan Area 4 showing location of historic drill holes and 2020 drill holes indicating results reported in this press release (dark blue) and results pending (dark green). Main Zone alteration and outcrop at surface shown in pink, carbonatite veinlets shown in red. Note four historic holes in turquoise were not included in the 2014 resource.

Figure 3. Drill section showing results from L4D0118 and L4D0119. Drilling has intersected Main Zone 300 m down-dip of historic hole NLOFDH055 and shows stronger grades and heavy rare earth enrichment at depth

Figure 4. Drill section showing results from L4D0120 and L4D0121. Significant improvement of grade and thickness up-dip and down-dip of historic hole NLOFDH4097. Hole L4D0122 (pending results) will test Main Zone 100 m further down-dip

Metallurgical Program

A number of sequential processing stages have been recommended for treatment of the xenotime mineralization at Lofdal and include upfront sorting, magnetic separation, flotation and gangue acid leaching to produce a mineral concentrate. Each of these stages will be further evaluated during Term 1 with the initial focus on XRF and XRT sorting using a representative 18 tonne sample that was collected from trenches along 650 meters of strike length from the Area deposit.

X-Ray Fluorescence ("XRF") sorting tests are being undertaken by Rados International at their test facility in Pretoria, South Africa (Figure 4). Mineralization at Lofdal is amenable to XRF sorting by analyzing for yttrium which is directly related to the concentration of the heavy rare earth mineral xenotime. Detailed calibration tests were carried out using 500 individual rock particles from Area 4 to determine the relationship between concentrations of yttrium as determined from a handheld XRF analyzer and the Rados XRF analyzer. Data was used to develop a final algorithm that will determine the efficiency of the technology to eliminate waste from run-of-mine ("ROM") prior to milling and to further upgrade the ROM by sorting at specific cut-off grades.

The strong correlation between calculated %TREO as estimated from concentrations of yttrium from a handheld XRF analyzer, and the Rados analyzer is shown in Figure 4. Tests were carried out on three separate size fractions from 20 mm to 150 mm to determine the optimum size fraction for sorting. All test runs have been completed on 2.7 tonnes of representative sample and analyses are pending on all products to enable mass balance, grade and recoveries to be determined.

Figure 4. Rados test facility in Pretoria with observation deck to XRF feed hopper on left and final calibration algorithm showing correlation between Rados analysis for yttrium and %TREO

X-Ray Transmission ("XRT") sorting tests are being undertaken by IMS Engineering at their test facility in Johannesburg, South Africa using a Steinert KSS LXT sorter which incorporates laser sensor technology with XRT (Figure 5). Mineralization at Lofdal is amenable to XRT sorting by detection of higher density minerals which host the xenotime mineralization (predominantly carbonate minerals calcite, ankerite and dolomite). Detailed calibration tests were carried out using 750 individual rock particles from Area 4 to determine the relationship between %TREO as estimated from concentrations of yttrium from a handheld XRF analyzer and the Steinert XRT analyzer. Optimization of the sorting algorithm will be finalized using laser sensors in conjunction with XRT to develop a final algorithm that will determine the a series of cut points to produce three final products targeting i) maximum recovery, ii) high grade and iii) a balance between recovery and grade. Tests Will be carried out on three separate size fractions from 10 mm to 80 mm to determine the optimum size fraction for sorting. A total of 4.4 tonnes of representative sample has been provided for the test program.

Figure 5. IMS test facility in Johannesburg showing feeder conveyor to XRT sorter on left and Lofdal bulk sample ready for screening on right

Namibia Critical Metals is the operator for the Lofdal Joint Venture with JOGMEC and will provide updates on the progress of the drilling and metallurgical programs as results become available.

About Namibia Critical Metals Inc.

Namibia Critical Metals Inc. holds a diversified portfolio of exploration and advanced stage projects in the country of Namibia focused on the development of sustainable and ethical sources of metals for the battery, electric vehicle and associated industries. The Company also has significant land positions in areas favourable for gold mineralization.

At the Erongo Gold Project, stratigraphic equivalents to the sediments hosting the recent Osino gold discovery at Twin Hills have been identified but not yet sampled. Soil surveys are progressing over this highly prospective area.

In addition to Lofdal, the Epembe Tantalum-Niobium Project is also at an advanced stage with a well-defined, 10 km long carbonatite dyke that has been delineated by detailed mapping with over 11,000 meters of drilling. Preliminary mineralogical and metallurgical studies including sorting tests (XRT), indicate the potential for significant physical upgrading. Further work will be undertaken to advance the project to a preliminary economic assessment stage.

The Kunene Cobalt-Copper Project comprises a very large area of favorable stratigraphy ("the DOF") along strike to the west of the Opuwo cobalt-copper-zinc deposit. Secondary copper mineralization over a wide area points to preliminary evidence of a regional-scale hydrothermal system. Exploration targets on EPLs held in the Kunene project comprise direct extensions of the DOF style mineralization to the west, sediment-hosted cobalt and copper, orogenic copper, and stratabound manganese and zinc-lead mineralization.

Earlier stage projects include the Grootfontein Base Metal and Gold Project which has potential for magmatic copper-nickel mineralization, Mississippi Valley-type zinc-lead-vanadium mineralization and Otjikoto-style gold mineralization. Detailed interpretation of geophysical data and regional geochemical soil sampling surveys are under way.

The common shares of Namibia Critical Metals Inc. trade on the TSX Venture Exchange under the symbol "NMI".

Donald M. Burton, P.Geo. and President of Namibia Critical Metals Inc., is the Company's Qualified Person and has reviewed and approved this press release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information please contact –

Namibia Critical Metals Inc.

Don Burton, President
Tel: +01 (902) 835-8760
Fax: +01 (902) 835-8761
Email: Info@NamibiaCMI.com
Web site: www.NamibiaCriticalMetals.com

The foregoing information may contain forward-looking information relating to the future performance of Namibia Rare Earths Inc. Forward-looking information, specifically, that concerning future performance, is subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company's filings with the appropriate securities commissions.

SOURCE: Namibia Critical Metals Inc.

ReleaseID: 594370

LANGLEY, BC / ACCESSWIRE / June 18, 2020 / Adastra Labs Holdings Ltd. (CSE:XTRX) (FRA:D2EP) ("Adastra", "XTRX", or the "Company") a Health Canada Licensed cannabis processing and analytical testing company announced today that it will be conducting a non-brokered private placement of units (the "Units") at a price of $0.30 per Unit for gross proceeds of up to $1,000,000 (the "Offering"), subject to the acceptance of over-allotments as described below.

Each Unit will be comprised of one common share in the capital of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"). Each Warrant shall be exercisable to acquire one Common Share (a "Warrant Share") at a price per Warrant Share of $0.50 for a period of 24 months from the date of issuance.

Provided that the closing price of the Common Shares exceeds $0.70 per share for 10 consecutive trading days on the CSE, then the expiry date of the Warrants will be accelerated at the Company's option to the date that is 30 days after the date the Company provides notice by press release to the holders of the Warrants.

The Units to be issued under the financing will be subject to a four month and one day hold period. There is no minimum offering amount. The Company may close the Offering in one or more tranches. The Company may pay commissions or finder fees on the amount raised through the Offering. The Company has authorized the acceptance of any over allotted subscriptions under the Offering subject to the condition that the total Offering after taking into account any over allotments shall not exceed $2,000,000. The terms of the financing are subject to applicable securities laws and regulatory approval.

Additionally, the Company announces that it has entered into agreements to settle outstanding indebtedness of $543,715 through the issuance of 1,941,840 common shares of the Corporation at a deemed price of $0.28 per common share (the "Debt Settlement"). The common shares issued in connection with the Debt Settlement are subject to a hold period that expiring four months and one day from the date of issuance.

The Company intends to use the proceeds of the Offering to fund equipment expansion, marketing expenses and for general working capital.

About Adastra Labs Holdings Ltd.

Adastra Labs Holdings Ltd. is a Langley, BC-based cannabis company with a co-located Health Canada Licensed Standard Processing Facility and Analytical Testing Laboratory. Adastra can produce cannabis extract through supercritical CO2 extraction and secondary distillation as well as conduct in-process quality testing. Such extracts can easily be incorporated into edibles, beverages, topicals, tinctures, vape cartridges and other products that will serve the Canadian medical and adult-use cannabis markets.

www.adastralabs.ca

On behalf of the Board of Directors of the Company,

Andrew Hale
Chief Executive Officer
Adastra Labs Holdings Ltd.
Phone: (778) 715-5011
Email: andy@adastralabs.ca

Address: 5451 275th Street, Langley, BC V4W 3X8
Telephone: 778-715-5011
Fax: 844-874-9893

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: Adastra's expectations concerning fulfilling its obligations under its agreements, purchase orders and receiving the economic benefits of such agreements or purchase orders. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Adastra assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

SOURCE: Adastra Labs Holdings Ltd.

ReleaseID: 594442

NEW YORK, NY / ACCESSWIRE / June 18, 2020 / It takes vision to identify a good idea, but it takes courage to see that idea through. This is what differentiates Paul Vigario, the founder of SurfCT, from the average person.

When he was studying at the University of Connecticut to get his degree in Management and Computer Information Systems with a focus on healthcare technology, the idea of a full service IT company for private practitioners came up in class.

"Everyone in class agreed it was a good idea for a doctor in private practice to have a full healthcare focused IT department as a resource, but no one thought it could be done. I took that idea and pulled it off, working day and night and starting the business out of my college dorm." Paul Vigario shares.

In his class, two questions had been asked: could a doctor in private practice benefit from a full IT department? To which everyone responded "yes." Was it financially feasible for a doctor in private practice to have a full IT department? To which everyone responded "no."

"I thought, if it was a good idea, why let money get in the way? I went to the local hospital and learned how they did it, and I came back to class and said it was a good idea, that it may not seem possible at first glance but we should never let money get in the way of a good idea. I showed them how to make it happen, and I did it!" Paul recounts.

Today, Paul Vigario founded and runs SurfCT, the number one dental information technology company. No one understands dental technology, digital workflow and practice automation like SurfCT.

"Dentists and healthcare industry leaders look for ways to innovate in the dental industry, but we had already been innovating since 2003. And that's over 2 decades of experience in dental technology, dental office design, dental systems and innovation where everything is connected" Paul shares.

SurfCT is an award-winning and internationally recognized company. They are a dental information technology company that helps doctors connect and automate everything in their private practice.

"Our ability to automate a practice makes us the technology company of choice for dentists, oral surgeons, orthodontists, optometrists, plastic surgeons, and even veterinarians seek us when they speak to a dentist friend who has shared what SurfCT has done for them. Our growth has been from happy doctors who have experienced the results of practice automation and practice growth by leveraging SurfCT knowledge and experience" Paul explains.

Paul started back when he was 20 years old, and there was a lot he did not know. That was his biggest challenge when he was starting. But he kept an open mind and was always learning and growing. To this day, he enjoys the journey more than the destination.

"Mindset is everything when you are starting." Paul says. "At SurfCT we say ‘Everything Is Connected™.' Some people think we are talking about IT, technology and computers, and we are. But it is more than that. It's about quality of life, relationships, friends, family, growth and redefining what's possible."

Paul's advice for those trying to start their own business or brand is to do it because you love it, because it is a true passion of yours, rather than for the money. For him, the money is a by-product of doing what he loves, helping doctors and practices achieve their goals.

"If you don't love what you are doing, it's not going to happen for you because someone out there will love it and they will beat you." Paul claims.

This is why SurfCT is the best at what they do, because they love what they do and always work to be number one. That mix of knowledge and execution is special. They are always growing the brand by taking care of their dentists, doctors and clients. Being client centric and building systems to help those clients is what makes them different.

"There is no comparison with what we do. We build systems for doctors, for the way they want to practice. We change their lives with practice automation. There really is no competition for SurfCT." Paul explains. "Most private practices before they meet us run like a local coffee shop. With our systems, we turn them into Starbucks. Does Starbucks compete with the local coffee shop owner?"

The next projects for Paul are to continue to focus on SurfCT , helping to expand what's possible in dentistry, while enjoying time with his family. He loves working with doctors and spending time with his three-year-old daughter. For him, success is about being happy and money is about time. With money, he gets more time, more options and more choices. This allows him to be happy as he is the happiest when he is with his family doing the things they love.

Find out more about Paul and how you can leverage the knowledge and power of SurfCT here.

CONTACT:

Paula Henderson
202-539-7664
phendersonnews@gmail.com

About VIP Media Group:

VIP Media Group is a hybrid PR agency. Their diverse client base includes top-class entrepreneurs, public figures, influencers, and celebrities.

SOURCE: VIP Media Group

ReleaseID: 594443

BALA CYNWYD, PA / ACCESSWIRE / June 18, 2020 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

resTORbio, Inc. (NasdaqGS:TORC)

Under the terms of the agreement, Adicet shareholders are expected to own approximately 75% of the combined company, and resTORbio shareholders are expected to own only 25%.

Additional information can be found at http://www.brodskysmith.com/cases/restorbio-inc-nasdaqgs-torc/, or call 877-534-2590. No cost or obligation to you.

Grubhub Inc. (NYSE:GRUB)

Under the terms of the agreement, Grubhub shareholders will receive 0.6710 Just Eat Takeaway.com ordinary shares in exchange for each Grubhub share, representing an implied value of $75.15 for each Grubhub share they own. The investigation concerns whether the Grubhub Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Just Eat Takeaway.com is underpaying for the Company. For example, the deal price is below the 52-week high of $80.25 for Grubhub shares, and at least one analyst covering Grubhub has set a target of $95.00 per share.

Additional information can be found at http://www.brodskysmith.com/cases/grubhub-inc-nyse-grub/, or call 877-534-2590. No cost or obligation to you.

Finjan Holdings, Inc. (NasdaqGS:FNJN)

Under the terms of the agreement, Finjan shareholders will receive only $1.55 for each share of Finjan they own. The investigation concerns whether the Finjan Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Fortress is underpaying for the Company. For example, the deal price is below the 52-week high of $2.40 for Finjan shares, and the 12-month average analyst price target for Finjan is $5.00 per share.

Additional information can be found at http://www.brodskysmith.com/cases/finjan-holdings-inc-nasdaqgs-fnjn/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 594439

VANCOUVER, BC / ACCESSWIRE / June 18, 2020 / Sebastiani Ventures Corp. (the "Company") (TSXV:SBS.H) announces that Rick Cox has been appointed as a director of the Company, and Scott Ackerman has been appointed as Chief Financial Officer, replacing Doug McFaul who has resigned as Chief Financial Officer and a director of the Company.

The Company wishes to thank Mr. McFaul for his service to the Company.

For further information, contact Scott Ackerman at 1-778-331-8505 or sackerman@emprisecapital.com.

On Behalf of the Board of Directors of:

SEBASTIANI VENTURES CORP.

Scott Ackerman
Director
Sebastiani Ventures Corp.
Email: sackerman@emprisecapital.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

SEBASTIANI VENTURES CORP.
1600 – 609 Granville Street
Vancouver, British Columbia V7Y 1C3

SOURCE: Sebastiani Ventures Corp.

ReleaseID: 594441

TORONTO, CANADA / ACCESSWIRE / June 18, 2020 / StageZero Life Sciences Ltd. (TSX:SZLS) ("StageZero", or the "Company") has filed its amended and restated management discussion and analysis ("MD&A") and interim financial statements for the three month period ended March 31, 2020 (collectively, the "Amended Filings") to provide more detailed analysis than the original MD&A and interim financial statements for the three months ended March 31, 2020 filed on June 1, 2020.

The amendments in the Amended Filings include:

March 31, 2020

an adjustment to the fair value of certain convertible debentures and warrant liabilities as at March 31, 2020.

March 31, 2019

a reallocation of the purchase price for the remaining 50% of StageZero Life Sciences Inc. (formerly IDL) on March 4, 2016, resulting in an increase in deficit of US$1,039,349.
a revision to the valuation of the warrant liability associated with the June 8, 2018 convertible securities funding agreement (CSFA) with Lind Asset Management XI, LLC and corresponding adjustments to share capital and interest expense.
adjustments to right-of-use asset, rent receivable, amortization and interest charges.

About StageZero Life Sciences Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (nasal swab) and blood test analysis (antibody testing). The Company's full service, telehealth platform includes access to physicians and phlebotomist who can prescribe and draw samples for individuals and groups. As the Company provides COVID-19 testing during this pandemic, the Company continues making progress with its mission to eradicate late stage cancers through early detection. The Company's next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. www.stagezerolifesciences.com

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Company Contacts

James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1

Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd

ReleaseID: 594437

VANCOUVER, BC / ACCESSWIRE / June 18, 2020 / ECC Diversified Inc. (the "Company" or "ECC Diversified"), announces that Scott Ackerman has been appointed as Chief Financial Officer of the Company, replacing Doug McFaul who has resigned as Chief Financial Officer, President and a director of the Company.

The Company wished to thank Mr. McFaul for his service to the Company.

For more information please contact the Company at 778-331-8505 or email: sackerman@emprisecapital.com

On Behalf of the Board of Directors of ECC Diversified Inc.

Scott Ackerman
Director

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.

ECC DIVERSIFIED INC.

Suite 1600 – 609 Granville Street
Vancouver, BC V7Y 1C3
Telephone: 1-778-331-8505

SOURCE: ECC Diversified Inc.

ReleaseID: 594432

NEW YORK, NY / ACCESSWIRE / June 18, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Phoenix Tree Holdings Limited (NYSE:DNK)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/phoenix-tree-holdings-limited-loss-submission-form?prid=7425&wire=1
Lead Plaintiff Deadline: June 26, 2020
Investors affected purchased American Depositary Shares ("ADS") of Phoenix pursuant and/or traceable to prospectuses and registration statements issued in connection with the Company's January 2020 initial public offering

According to the filed complaint, the documents Phoenix Tree issued in connection with its initial public offering ("IPO") omitted or otherwise misrepresented the nature and level of renter complaints the Company had received before and as of the IPO, as well as the demand in the Chinese residential rental market and the Company's exposure to significant adverse developments resulting from the onset of the coronavirus in China – particularly in Wuhan – at the time of the IPO. After the IPO, reports emerged indicating that Phoenix was experiencing ongoing problems due to the coronavirus, which was causing financial and other harm to tenants.

Carnival Corporation & Plc (NYSE:CCL)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/carnival-corporation-loss-submission-form?prid=7425&wire=1
Lead Plaintiff Deadline: July 27, 2020
Class Period: September 26, 2019 – May 1, 2020

Allegations against CCL include that: (1) the Company's medics were reporting increasing events of COVID-19 illness on the Company's ships; (2) Carnival was violating port of call regulations by concealing the amount and severity of COVID-19 infections on board its ships; (3) in responding to the outbreak of COVID-19, Carnival failed to follow the Company's own health and safety protocols developed in the wake of other communicable disease outbreaks; (4) by continuing to operate, Carnival ships were responsible for continuing to spread COVID-19 at various ports throughout the world; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Wells Fargo & Company (NYSE:WFC)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/wells-fargo-company-loss-submission-form?prid=7425&wire=1
Lead Plaintiff Deadline: August 3, 2020
Class Period: April 5, 2020 – May 5, 2020

Allegations against WFC include that: (i) Wells Fargo planned to, and did, improperly allocate government-backed loans under the Paycheck Protection Program ("PPP"), and/or had inadequate controls in place to prevent such misallocation; (ii) the foregoing foreseeably increased the Company's litigation risk with respect to PPP allocation, as well as increased regulatory scrutiny and/or potential enforcement actions; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 594430